<DOC>
	<DOCNO>NCT01370369</DOCNO>
	<brief_summary>This open-label study single repeat application three dose level topical testosterone hypogonadal male morning serum testosterone concentration &lt; 297 ng/dL .</brief_summary>
	<brief_title>Efficacy , Pharmacokinetics Safety Testosterone</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Ages 1865 History hypogonadism In good health base medical history , physical examination clinical laboratory test Screening morning serum testosterone ≤ 297 ng/dL One symptoms testosterone deficiency ( i.e . fatigue , reduce libido reduce sexual functioning nonvasculogenic neurogenic nature ) Body mass index ( BMI ) 18 31 Prostate cancer Palpable prostatic mass ( e ) Generalized skin irritation significant skin disease Use medication could consider anabolic ( e.g . dehydroepiandrosterone ( DHEA ) ) could interfere androgen metabolism ( e.g . spironolactone , finasteride , ketoconazole ) Clinically significant anemia renal dysfunction Hyperparathyroidism uncontrolled diabetes Serum PSA Levels ; ≥ 4ng/mL History cardiovascular disease Use estrogens , Gonadotropinreleasing hormone ( GnRH ) agonists/antagonist , human growth hormone ( hGH ) , ( within previous 12 month ) Use testosterone product ( within eight month parenteral product , six week preparation )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>